# Septodont and Acteon Group acquire Inibsa

Septodont and Acteon Group signed an agreement to acquire Inibsa, a Spanish pharmaceutical laboratory specializing in dental products. Septodont will hold 51% and Acteon Group 49%. Announced November 5, 2024.

- Type: Acquisition
- Announced: 2024-11-05
- Where: Barcelona, Spain
- Status: announced
- Products: dental products
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Inibsa Group](https://endata.com/companies/21123.md) (target)
- [Septodont](https://endata.com/companies/23657.md) (acquirer)
- [Acteon](https://endata.com/companies/38654.md) (acquirer)
- [Laboratorios Inibsa](https://endata.com/companies/81301.md) (target)

## Sources

- [de-pardieu.com](https://www.de-pardieu.com/en/de-pardieu-advises-acteon-groupon-the-signing-of-an-agreement-with-septodont-for-the-acquisition-of-inibsa-phamaceutical-laboratory-specializing-in-dental-products/), 2024-11-05: "Septodont will be the controlling shareholder of Inibsa, while Acteon Group will be a partner and reference shareholder."
- [iberianlawyer.com](https://iberianlawyer.com/dentons-advises-septodont-on-the-acquisition-of-spanish-laboratories-inibsa/), 2024-11-25: "This acquisition of control of Inibsa will expand Septodont's development in dental products and help us further strengthen our geographical footprint."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.